



Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
Epoetin lambda	Anaemia Chronic kidney failure	Eporex® brand of epoetin alfa (Janssen-Cilag)	Novicrit® (Sandoz)	01/08/2010 (pre-dated current PBAC approach to advice on 'a' flagging)
Filgrastim	Haematopoietic stem cell transplantation Chemotherapy induced neutropoenia	Neupogen® (Amgen) 'a' flagged	Nivestim® (Pfizer) 'a' flagged	01/04/2011
			Zarzio® (Sandoz) 'a' flagged	01/09/2013
Infliximab	Ankylosing spondylitis Crohn's disease Psoriatic arthritis Psoriasis Rheumatoid arthritis Ulcerative colitis	Remicade® (Janssen- Cilag) 'a' flagged	Inflectra® (Pfizer) 'a' flagged	01/12/2015
			Renflexis® (Merck Sharp and Dohme) 'a' flagged	01/08/2017
Follitropin alfa	Infertility treatment	Gonal-r® (Merck Serono Australia)	Bemfola® (Gedeon Richter)	01/08/2016
			Ovaleap® (Theramex) 'a' flagged	01/12/2021
Etanercept	Ankylosing spondylitis Psoriatic arthritis Psoriasis Rheumatoid arthritis Juvenile idiopathic arthritis (note this indication treated by Enbrel only)	Enbrel® (Pfizer) 'a' flagged	Brenzys® (Merck Sharp and Dohme) 'a' flagged	01/04/2017
Trastuzumab†	Breast cancer Gastric cancer	Herceptin® (Roche) (note this brand (IV) no longer available on the PBS)	Ogivri® (Alphapharm)	01/08/2019
			Herzuma® (Celltrion)	01/11/2019

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
			Kanjinti® (Amgen)	01/12/2019
			Ontruzant® (Merck Sharp and Dohme)	01/01/2020
			Trazimera® (Pfizer)	01/05/2020
Rituximab†	CD20 positive follicular B-cell non-Hodgkin's lymphoma Severe active granulomatosis with polyangiitis (Wegeners granulomatosis) CD20 positive non-Hodgkin's lymphoma Low-grade B-cell non-Hodgkin's lymphoma Chronic lymphocytic leukaemia Severe active rheumatoid arthritis Severe active microscopic polyangiitis	MabThera® (Roche) 'a' flagged (note this brand no longer available on the PBS)	Riximyo® (Sandoz) 'a' flagged (s100)	01/10/2019
			Truxima® (Celltrion) 'a' flagged (s100)	01/01/2020
			Ruxience® (Pfizer) 'a' flagged (s100)	01/06/2022
Pegfilgrastim	Haematopoietic stem cell transplantation Chemotherapy induced neutropenia	Ristempa® (Juno) 'a' flagged	Ziextenzo® (Sandoz) 'a' flagged	01/03/2020
			Pelgraz® (Accord) 'a' flagged	01/08/2020
Adalimumab	Severe Crohn disease Moderate to severe ulcerative colitis Severe active juvenile idiopathic arthritis Complex refractory fistulising Crohn disease Severe active rheumatoid arthritis Severe psoriatic arthritis Ankylosing spondylitis Severe chronic plaque psoriasis Moderate to severe hidradenitis suppurativa.	Humira® (AbbVie) 'a' flagged	Amgevita® (Amgen) 'a' flagged	01/04/2021
			Hadlima® (Samsung Bioepis) 'a' flagged	01/04/2021
			Hyrimoz® (Sandoz) 'a' flagged	01/04/2021
			Idacio® (Fresenius Kabi) 'a' flagged	01/04/2021
Bevacizumab	Metastatic colorectal cancer Stage IV (metastatic) non-small cell lung cancer (NSCLC) Relapsed or recurrent glioblastoma	Avastin® (Roche)® (note this brand no longer available on the PBS)	Mvasi® (Amgen)	01/06/2021

Active ingredient	Therapeutic Area Treated by Active Ingredient*	Reference brand (Sponsor)	Biosimilar brand (Sponsor)	Date of PBS listing for biosimilar brands
	Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer Advanced carcinoma of cervix			
Teriparatide	Osteoporosis in postmenopausal women; Primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fracture; and Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.	Forteo® (Eli Lilly) (note this brand no longer available on PBS)	Terrosa® (Gedeon Richter)	01/10/2021

Data correct as 1 June 2022.

* Refer to the Schedule of Pharmaceutical Benefits to identify indications for which the reference brand and biosimilar brand are available for subsidised access (all brands may not be available for all indications).

† The independent expert Pharmaceutical Benefits Advisory Committee (PBAC) recommended Herzuma® and Ogivri® be listed on the PBS as substitutable biosimilars of the Herceptin® reference brand of trastuzumab for the purposes of the Efficient Funding of Chemotherapy Program. The PBAC also recommended Riximyo® and Truxima® be listed as substitutable biosimilars of the MabThera® reference brand of rituximab on this Program. Under section 33(2) of the *National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011*, chemotherapy medicines supplied under the Efficient Funding of Chemotherapy program may be substituted with a different brand of the same chemotherapy medicine. These medicines are not marked with 'a'-flags in the Schedule of Pharmaceutical Benefits.